Silence Therapeutics PLC SLN124 granted Orphan Drug Designation by EMA (0750N)

TIDMSLN

RNS Number : 0750N

Silence Therapeutics PLC

15 January 2019

SLN124 granted Orphan Drug Designation by EMA for the treatment of <BETA>-Thalassemia

January 15, 2019

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that its lead medicine candidate SLN124 has been granted Orphan Drug Designation by the Committee for Orphan Medicinal Products (COMP), the European Medicines Agency's (EMA) committee responsible for recommending orphan designations of medicines for rare diseases. This positive COMP decision has been adopted by the European Commission.

Following an application by Silence last year, the COMP concluded that SLN124 will be of significant benefit to those affected by the chronic and potentially life-threatening condition, <BETA>-Thalassemia. By receiving Orphan designation, SLN124 can benefit from expediated clinical development and ten years of market exclusivity, subject to approval. The COMP decision follows positive feedback from the UK Medicines and Healthcare products Regulatory Agency (MHRA) Scientific Advice meeting in June last year.

SLN124, which has been shown to lower serum iron levels and modulate tissue iron distribution in rodent models for <BETA>-Thalassemia and hereditary hemochromatosis, represents a promising therapeutic candidate for treating patients with iron overload disorders, including <BETA>-Thalassemia, myelodysplastic syndrome (MDS) and hereditary hemochromatosis.

Dr. David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"We are pleased to receive Orphan Drug Designation for our iron overload disorder candidate, SLN124, which will assist in expediting clinical development as we progress our Phase Ib trial planned to begin in H2 2019. We believe that this innovative product offers significant promise for patients with iron overload disorders such as <BETA>-Thalassemia, MDS and hereditary hemochromatosis and we look forward to rapidly advancing SLN124 through clinical development."

Enquiries:

 
 Silence Therapeutics plc                       Tel: [phone] 
  Dr David Horn Solomon, Chief Executive         6900 
  Officer 
 
 Peel Hunt LLP (Nominated Adviser and Broker)   Tel: [phone] 
  James Steel/Oliver Jackson                     8900 
 European IR                                    Tel: +44 (0) 20 
  Consilium Strategic Communications             3709 5700 
  Mary-Jane Elliott / Angela Gray 
  [e-mail] 
 US IR                                           Tel: [phone] 
  Westwicke Partners 
  Peter Vozzo 
  [e-mail] 
 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RESDDGDBGDBBGCS

(END) Dow Jones Newswires

January 15, 2019 02:00 ET (07:00 GMT)